HOUSE_OVERSIGHT_028418.jpg

pitch its story to Wall Street. It settled on Mr. Hugin, a managing director at J.P. Morgan.","type":"text"}, {"bannerType"™:"any", "identifier":" anf-banner advertisement 5","layout"™:"ComponentLayout-— 4","role":"banner advertisement", "type":"banner advertisement"}, {"additions":[{"URL™:"h ttps://bobhugin.com/about/", "range": {"length":19,"start":176},"type":"Llink"}, ("URL":"ht tps://www.sec.gov/Archives/edgar/data/816284/000100515000000449/0001005150-00- 000449.txt", "range": {"length":21,"start":223},"type"™:"link"}],"identifier":" anf-body- 27","inlineTextStyles": [{"range"™:{"length":461,"start":0},"textStyle":"_ anf-ts- i"},{"range"™:{"length":461,"start":0},"textStyle":" anf-ts-1"}],"layout":"default- body", "role": "body", "text": "At the time, the companyde€™s financial situation was perilous. Celgene had 200 employees and was getting by on less than six weeks of cash when Mr. Hugin joined, according to his campaign biography. A year later, the company warned investors that, a€eduring the next several years, we will be very dependent on the commercial success of Thalomid,d4€ while also acknowledging that the market for the only disease for which the drug was approved was a€erelatively small.a€","type":"text"™}, {"identifier":" anf-heading4- 2","layout":"heading4", "role": "heading4", "text":"Seeking a windfall by exploiting drug safety rules", "type":"text"}, {"identifier"™:" anf-body- 28","inlineTextStyles": [{"range":{"length":387,"start":0},"textsStyle":"_ anf-ts- i"}, {"range™: {"length":387,"start":0},"textStyle":"_anf-ts-1"}],"layout":"default-— body", "role":"body", "text":"Drug companies are forbidden from promoting a drug for any unapproved uses, but doctors have broad discretion to prescribe a product for a range of diseases. Celgene appeared to exploit this distinction almost as soon as Thalomid arrived on the market, according to company filings, public statements and internal documents included in the whistle-blower lawsuit Celgene settled in 2017.","type":"text"}, {"identifier":" anf-body- 29","inlineTextStyles": [{"range"™:{"length":257, "start":0},"textsStyle":"_ anf-ts- i"}, {"range™:{"length":257,"start":0},"textStyle":" anf-ts-1"}],"layout":"default- body", "role":"body", "text":"The company hired a team of 60 sales representatives, many of whom had experience in oncology, according to financial filings, and just months after Thalomid arrived on the market, Celgene announced that it would pursue F.D.A. approval for multiple myeloma.", "type": "text"}, {"components": [{"caption":"Mr. Hugin has defended his role as a top executive at Celgene, saying that he helped lead a company that developed life-saving medicines. Rick Loomis for The New York Times", "captionComponent": {"text":"Mr. Hugin has defended his role as a top executive at Celgene, saying that he helped lead a company that developed life-saving medicines. Rick Loomis for The New York Times"},"identifier™:"100000006098033 Sba8b804122ca", "imageldentifier"™:"c275d4ffab4cd56 96e6a2645c43f84a0", "Layout": "fullbleed- image", "role":"photo", "type": "scalable image"}, {"identifier":" anf-caption- 3","inlineTextstyles": [{"range": {"length":35, "start":138}, "textstyle": "photo- credit"}],"layout":"default-caption", "role": "caption", "text":"Mr. Hugin has defended his role as a top executive at Celgene, saying that he helped lead a company that developed life-saving medicines. Rick Loomis for The New York Times ","type™:"text"}],"identifier":" anf-container-2", "layout": "image- container", "role":"container", "type": "container"}, {"additions"™: [{"URL":"http://wayback. archive- it.org/7993/20170112071439/http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulat oryiInformation/EnforcementActivitiesbyFDA/WarningLettersandNoticeofViolationLetterstoPh armaceuticalCompanies/UCM167840.pdf", "range": {"length":47,"start":100}, "type":"link"}, { "URL": "https://www.washingtonpost.com/archive/politics/2000/05/05/fda-moves-to-curb ads-for-thalidomide/dd6ce44a-711b-424c-a9a0 ae67168f170c/?utm term=.f0af824af352", "range": {"length":16,"start":246},"type™:"Llink"}] ,"identifier":" anf-body- 30","inlineTextStyles": [{"range": {"length":319, "start":0},"textsStyle":"_ anf-ts- i"}, {"range™:{"length":319,"start":0},"textStyle":" anf-ts-1"}],"layout":"default- body", "role":"body", "text":"The F.D.A. reprimanded Celgene multiple times in those early years, telling the company that it had not adequately warned about thalidomideade™s risks in its announcement about multiple myeloma, and calling a meeting in December 1998 to warn of its A€estrong concernd€ that Celgene was marketing Thalomid for unapproved uses.","type":"text"}, {"bannerType"™:"any", "identifier"™:" anf- banner advertisement-6", "layout": "ComponentLayout— 4","role":"banner advertisement", "type":"banner advertisement"}, {"additions": [{"URL™:"h ttp://wayback.archive- it.org/7993/20170112070734/http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulat oryiInformation/EnforcementActivitiesbyFDA/WarningLettersandNoticeofViolationLetterstoPh armaceuticalCompanies/UCM165843.pdf", "range": {"length":41, "start ":9},"type™:"link"}],"i HOUSE_OVERSIGHT_028418